-
公开(公告)号：US20220392940A1
公开(公告)日：2022-12-08
申请号：US17761981
申请日：2020-09-11
Inventor： Paisan KHANCHAITIT , Kittipong TANTISANTISOM , Sattra THONGMA , Thitikorn BOONKOOM , Kanpitcha JIRAMITMONGKON , Yossawat RAYANASUKHA , Supone MANAKASETTHARN , Preedee PINPRADUP , Thanakorn JIEMSAKUL , Nachat JATUSRIPITAK , Naranpraphai SUTHISAMPHAT , Supaporn KLUNGTHONG
IPC: H01L27/146 , G02B3/00
Abstract: An apparatus for microneedle fabrication by the microlens technique is disclosed. The apparatus leads to a reduction in production time, cost and damage of microneedle which may be from demolding step in the molding technique. A microlens container, transparent sphere, medium, substrate sheet, and photopolymer is also disclosed. A microneedle fabrication processes capable of producing microneedles with different heights by adjusting focal length of the micro lens is further disclosed. The focal length can be adjusted by 1) changing spacing between the microlens and the substrate sheet and 2) selecting the medium with different refractive index which results in the refractive index ratio of the transparent sphere to the medium between 1.0 and 1.5. Furthermore, different pattern and shape of microneedle can be achieved by changing the arrangement of the transparent sphere instead of using photomask.
-
2.发明申请公开(公告)号：US20200239445A1
公开(公告)日：2020-07-30
申请号：US15762530
申请日：2016-09-16
Inventor： Sumalee KAMCHONWONGPAISAN , Netnapa CHAROENSETAKUL , Krisana PEEWASAN , Jarunee VANICHTANANKUL , Roonglawan RATTANAJAK , Supannee TAWEECHAI , Tosapol ANUKUNWITHAYA , Aphisit YOOMUANG , Yongyuth YUTHAVONG , Tirayut VILAIVAN
IPC: C07D403/04 , C07D413/12 , C07D417/12 , A61P33/06
Abstract: The present invention relates to 2,4-diamino-6-ethylpyrimidine derivatives that are inhibitors of wild type and quadruple mutant dihydrofolate reductase (DHFR) of Plasmodium falciparum. They also show in vitro antimalarial activities against Plasmodium falciparum for both wild type and mutant that are comparable to or better than pyrimethamine. In addition, the compounds of the present invention show a good selectivity to Plasmodium falciparum and exhibit lower cytotoxicity than pyrimethamine.
-
公开(公告)号：US20220340630A1
公开(公告)日：2022-10-27
申请号：US17642422
申请日：2020-07-17
Inventor： Katanchalee MAI-NGAM , Satrawut CHAROENLA , Warobon NOPPAKUNMONGKOLCHAI , Ubolsree LEARTSAKULPANICH , Rachaneegorn GESORN
IPC: C07K14/495 , C07K1/02 , C07K1/22
Abstract: A composition of renaturation buffer solution for dimeric proteins and method for using it. The renaturation buffer solution comprises buffer, oxido shuffling system, primary additives, chelating agent and polysorbate compound. The method for renaturation of dimeric proteins includes solubilization of target proteins using a solubilization buffer, solution dilution of the renatured target protein using a renaturation buffer containing polysorbate compound(s), concentrating of the target protein solution to a concentration approaching saturation. A method of applying renature denatured or misfolded proteins to become correctly folded and bioactive. A method of proper renaturation of recombinant proteins that have been expressed using translation vehicles (e.g., bacteria, insects, etc.) and proteins damaged by mechanical shearing, chemical stresses, and other stresses.
-
公开(公告)号：US20210324013A1
公开(公告)日：2021-10-21
申请号：US17262327
申请日：2019-05-28
Inventor： Nopporn SITTISOMBUT , Malinee SAE-LIM , Nicha CHAROENSRI , Poonsook KEELAPANG
IPC: C07K14/005 , C12N7/00 , A61K39/12 , A61P31/14
Abstract: The present disclosure associates to a modified and expressed virus-like particles. Particularly, the virus-like particle is capable of eliciting immune response in a mammal upon administrating a pharmaceutically efficient dosage to the mammal. The virus-like particle comprises a modified form of M and E structural proteins of flavivirus. Further, the virus-like particle comprises an amino acids sequence substantially corresponding to a sequence setting forth in SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4, wherein conserved and internally located His at multiple positions of the M and E proteins are substituted with uncharged residues, and other secretion-enhancing substitutions are introduced.
-
公开(公告)号：US10011842B2
公开(公告)日：2018-07-03
申请号：US15025881
申请日：2014-09-18
CPC classification number: C12N15/70 , C12N9/003 , C12N9/1007 , C12N9/1085 , C12N9/1235 , C12N9/93 , C12Q1/48 , G01N2333/91017 , G01N2333/91165 , G01N2333/91171
Abstract: In this invention, cell lines are created for enzyme inhibitory testing of inhibitors against Plasmodium falciparum DHFR-TS and HPPK-DHPS. Provided the complementing DHFR-TS and HPPK-DHPS have sufficient activities to support growth of the surrogates in un-supplemented medium, the same surrogates could be used for screening inhibitors of targets against other parasite and pathogen species e.g. Plasmodium vivax, Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii or Mycobacterium tuberculosis. The cell lines in this invention are Escherichia coli strain whose thyA, folA, folK, and folP genes were disrupted using genetic knockout coupled with elimination of antibiotic resistance markers. The thyA KO, folP KO, folK KO, thyAfolA KO, folKfolP KO, thyAfolAfolP KO, thyAfolAfolK KO and thyAfolAfolKfolP KO E. coli cell lines are easy and convenient for testing single and combination drugs as plasmids bearing complementing parasite genes can be introduced simply by transformation using standard antibiotic selection.
-
Patent Agency Ranking
公开(公告)号：US09834772B2
公开(公告)日：2017-12-05
申请号：US15027970
申请日：2014-10-15
Inventor： Deanpen Japrung , Tararaj Dharakul , Suchintana Chumseng
IPC: C12N15/11 , C12N15/115
CPC classification number: C12N15/115 , C12N2310/16 , C12N2310/3517
Abstract: This invention is about the selection and development of aptamers that specifically bound HSA and GHSA. HSA and GHSA are associated with diabetes mellitus. The length of selected aptamers are around 46-106 bases, in which aptamers against HSA are consisting of 46-106 bases and aptamers against GHSA are consisting of 49-71 bases. All selected aptamers against HSA and GHSA can be potentially applied for detection and monitoring of diabetes mellitus in combination with blood glucose and HbA1C level. They also can applied in the drug development and drug delivery system in the diabetes mellitus and Alzheimer disease. In addition, chemical or fluorescence labeled these aptamers can be used for study function and location of HSA and GHSA.
-
公开(公告)号：US09452428B2
公开(公告)日：2016-09-27
申请号：US14534502
申请日：2014-11-06
Inventor： Mana Sriyudthsak , Apinan Soottitantawat , Yongyuth Wanna , Sakon Rahong , Vichuta Lauruengtana , Naoki Ichikawa , Sohei Matsumoto , Ryutaro Maeda
CPC classification number: B01L3/502707 , B01L3/5027 , B01L2200/10 , B01L2300/0636 , B01L2300/0645 , B01L2300/0663 , B01L2300/0816 , B01L2300/0887 , C12Q1/25
Abstract: A microfluidic device allowing for multiple discrete reactions sites and allowing for sequential reactions and sample analysis along with methods for device fabrication and use is provided. The microfluidic device provides a micro-total analysis system on a single substrate and has multiple reaction sites allowing for cascade reactions and analysis on a single chip using micro-quantities of sample and reagents. The microfluidic device provides discrete sites for immobilization of cognitive agents including enzymes, binding proteins, nucleic acids and the like as well as methods for quantitative analysis. The invention also provides methods for the fabrication of the device.
Abstract translation: 提供了允许多个离散反应位点和允许顺序反应和样品分析以及用于器件制造和使用的方法的微流体器件。 微流体装置在单个底物上提供微量分析系统，并具有多个反应位点，允许使用微量的样品和试剂在单个芯片上进行级联反应和分析。 微流体装置提供用于固定认知剂（例如酶，结合蛋白，核酸等）的离散位点以及用于定量分析的方法。 本发明还提供了用于制造该装置的方法。
-
![[5]Helicene derivatives as molecular reporters for diagnostic applications and methods of synthesis therefor](/abs-image/US/2023/02/14/US11578040B2/abs.jpg.150x150.jpg)
公开(公告)号：US11578040B2
公开(公告)日：2023-02-14
申请号：US16338031
申请日：2017-09-29
Inventor： Thanasat Sooksimuang , Nitsara Karoonuthaisiri , Ratthaphol Charlermroj , Somboon Sahasithiwat , Waraporn Panchan , Manlika Makornwattana , Sudtida Phuengwas , Laongdao Kangkaew
IPC: G01N21/76 , C07D209/58 , C07C255/54 , C07C309/11 , G01N33/58 , A61B5/00
Abstract: The present invention provides the methods of synthesis of [5]helicene compounds and the use of the said compounds conjugating with biomolecules to work as molecular reporter for diagnostic. The compounds in the present invention have the chemical structure illustrated in the formula (1): wherein G is a connecting group composes of 2 carbon atoms selected from the group consisting of ethane and ethylene; A is a separated or connected group selected from the group consisting of cyano and imide; D1 is selected from the group consisting of oxyalkanoic acid, oxyalkanal and oxyalkanesulfonate; and D2 has structure selected from the group consisting of hydroxyl, oxyalkanoic acid, oxyalkanal, alkyl oxyalkanoate, oxyalkanol and oxyalkanesulfonate. The compounds in the present invention compose of aromatic [5]helicene core comprising long it-conjugating system. The said compounds contain functional groups which able to link with biomolecules and they are soluble in water or other solvents that used in binding process with biomolecules. Moreover, owing to having proper chemical structure, the compounds in the present invention exhibit good fluorescent emission in wavelength of 425-675 nm. When the said compounds connected with biomolecules, the biomolecules give good fluorescence and can be detected under ultraviolet radiation.
-
公开(公告)号：US20150064688A1
公开(公告)日：2015-03-05
申请号：US14534502
申请日：2014-11-06
Inventor： Mana Sriyudthsak , Apinan Soottitantawat , Yongyuth Wanna , Sakon Rahong , Vichuta Lauruengtana , Naoki Ichikawa , Sohei Matsumoto , Ryutaro Maeda
CPC classification number: B01L3/502707 , B01L3/5027 , B01L2200/10 , B01L2300/0636 , B01L2300/0645 , B01L2300/0663 , B01L2300/0816 , B01L2300/0887 , C12Q1/25
Abstract: A microfluidic device allowing for multiple discrete reactions sites and allowing for sequential reactions and sample analysis along with methods for device fabrication and use is provided. The microfluidic device provides a micro-total analysis system on a single substrate and has multiple reaction sites allowing for cascade reactions and analysis on a single chip using micro-quantities of sample and reagents. The microfluidic device provides discrete sites for immobilization of cognitive agents including enzymes, binding proteins, nucleic acids and the like as well as methods for quantitative analysis. The invention also provides methods for the fabrication of the device.
Abstract translation: 提供了允许多个离散反应位点和允许顺序反应和样品分析以及用于器件制造和使用的方法的微流体器件。 微流体装置在单个底物上提供微量分析系统，并具有多个反应位点，允许使用微量的样品和试剂在单个芯片上进行级联反应和分析。 微流体装置提供用于固定认知剂（例如酶，结合蛋白，核酸等）的离散位点以及用于定量分析的方法。 本发明还提供了用于制造该装置的方法。
-
10.发明申请Three-color reagent for measurement of CD4 positive lymphocytes by flow cytometry 审中-公开用于通过流式细胞术测量CD4阳性淋巴细胞的三色试剂公开(公告)号：US20040110122A1
公开(公告)日：2004-06-10
申请号：US10461544
申请日：2003-06-16
Inventor： Watchara Kasinrerk
IPC: G01N033/53 , C12Q001/00
CPC classification number: G01N33/56972 , G01N33/533 , G01N2333/70514
Abstract: The developed reagent is three-color immunophenotyping reagent for measurement of CD4 positive lymphocytes in peripheral blood. The reagent contains 7-aminoactinomycin D (7-AAD) which intercalates into double stranded DNA and is easily excited at 488 nm. The fluorescence emission of 7-AAD has peak at 670 nm that can be detected with FL3 detector of flow cytometer. The 7-AAD, therefore, stains white blood cells and discriminates it from red blood cells. The reagent also contains fluorescein isothiocyanate (FITC) labeled CD4 monoclonal antibody and phycoerythrin (PE) labeled CD14 monoclonal antibody which are detected with FL1 and FL2 detectors of flow cytometer, respectively. The developed reagent can be used to measure number of CD4 positive lymphocytes in lymphocyte population and monitor monocyte contamination simultaneously. This reagent therefore provides more accuracy results of CD4 positive lymphocyte enumeration.
Abstract translation: 开发的试剂是用于测量外周血中CD4阳性淋巴细胞的三色免疫分型试剂。 该试剂含有插入双链DNA中的7-氨基生物素D（7-AAD），并且容易在488nm激发。 7-AAD的荧光发射峰值为670 nm，可用流式细胞仪的FL3检测器检测。 因此，7-AAD会染白细胞并将其与红细胞区分开来。 该试剂还分别含有荧光素异硫氰酸酯（FITC）标记的CD4单克隆抗体和藻红蛋白（PE）标记的CD14单克隆抗体，分别用流式细胞仪的FL1和FL2检测器检测。 开发的试剂可用于测量淋巴细胞群体中CD4阳性淋巴细胞的数量，并同时监测单核细胞污染。 因此，该试剂提供CD4阳性淋巴细胞计数的更准确的结果。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.017 seconds)
